Article ID | Journal | Published Year | Pages | File Type |
---|---|---|---|---|
5697239 | Brachytherapy | 2016 | 7 Pages |
Abstract
The dosimetric advantages to OARs offered by MRI-based brachytherapy with prescription to HR-CTV D90 compared to Point A is most distinct for patients with smaller HR-CTV (<25 cm3). This study demonstrates sufficient tumor coverage with lower doses to OARs in HR-CTV D90 vs. Point A plans in the small lesion group. These improvements were not seen in the large lesion group, indicating a lesser dosimetric advantage of HR-CTV D90 compared to Point A planning when the cervical lesion is >25 cm3. Incorporation of interstitial needles for patients with larger HR-CTV is likely the best method to decrease dose to OARs and improve tumor coverage.
Related Topics
Health Sciences
Medicine and Dentistry
Oncology
Authors
Grant Harmon, Abbie Diak, Steven M. Shea, Joseph H. Yacoub, William Jr., Matthew M. Harkenrider,